Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors

Organ transplant recipients are at higher risk for developing lymphoid tumors, skin carcinomas, and sarcomas. Whether liver transplant recipients are at higher risk for developing more common cancers is unclear.

[1]  U. Neumann,et al.  De novo malignancies after liver transplantation using tacrolimus‐based protocols or cyclosporine‐based quadruple immunosuppression with an interleukin‐2 receptor antibody or antithymocyte globulin , 1997, Cancer.

[2]  I. Penn.  Evaluation of the candidate with a previous malignancy. , 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[4]  I. Penn.  Posttransplantation de novo tumors in liver allograft recipients. , 1996, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  I. Popescu,et al.  A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. , 1995, Journal of the American College of Surgeons.

[6]  M. Tempero,et al.  Malignancies After Liver Transplantation: A Comparative Review , 1995, Seminars in liver disease.

[7]  J. Willner,et al.  The role of radiation therapy in the multidisciplinary management of recurrent and metastatic breast cancer , 1995, Cancer.

[8]  P. Heering,et al.  Malignancy under immunosuppressive therapy including cyclosporine. , 1994, Transplantation proceedings.

[9]  I. Penn.  The problem of cancer in organ transplant recipients: an overview. , 1994, Transplantation science.

[10]  S. Gruber,et al.  Etiology and pathogenesis of tumors occurring after organ transplantation. , 1994, Transplantation science.

[11]  J. Jessurun,et al.  Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease , 1993, Diseases of the colon and rectum.

[12]  I. Penn.  The effect of immunosuppression on pre-existing cancers. , 1993, Transplantation.

[13]  A. Sheil,et al.  De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. , 1993, Transplantation proceedings.

[14]  J. Gibbs,et al.  De novo malignancy following liver transplantation: a single-center study. , 1993, Transplantation proceedings.

[15]  R. Brunkhorst,et al.  Malignancies under cyclosporine after kidney transplantation: analysis of a 10-year period. , 1993, Transplantation proceedings.

[16]  W. Bennett,et al.  Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants. , 1993, Transplantation proceedings.

[17]  T. Starzl,et al.  Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. , 1992, Clinical transplantation.

[18]  I. Penn,et al.  Cancer in the immunosuppressed organ recipient. , 1991, Transplantation proceedings.

[19]  I. Penn.  The changing pattern of posttransplant malignancies. , 1991, Transplantation proceedings.

[20]  T. Starzl,et al.  Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. , 1991, Transplantation proceedings.

[21]  R. Fisher,et al.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.

[22]  J. Vandenbroucke,et al.  Incidence of skin cancer after renal transplantation in The Netherlands. , 1990, Transplantation.

[23]  I. Penn,et al.  Why do immunosuppressed patients develop cancer? , 1989, Critical reviews in oncogenesis.

[24]  R. Selik,et al.  Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. , 1987, AIDS.

[25]  H. Lithell,et al.  A longitudinal study of the pharmacokinetics of cyclosporine A and in vitro lymphocyte responses in renal transplant patients. , 1986, Transplantation proceedings.

[26]  I. Blohmé,et al.  Malignant disease in renal transplant patients. , 1985, Transplantation.

[27]  H. Sacks,et al.  Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. , 1984, The American journal of medicine.

[28]  I. Penn.  Depressed immunity and the development of cancer. , 1981, Clinical and experimental immunology.